-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Point/Counterpoint: The case for/against thrombophilia testing in many/most adults with unprovoked thrombosis.

Program: Spotlight Sessions
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Monday, December 12, 2022: 2:45 PM-4:00 PM
288-290 (Ernest N. Morial Convention Center)
Wendy Lim, MD, MSc, McMaster University
Lim: Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS-Pfizer Alliance: Honoraria; Aspen: Membership on an entity's Board of Directors or advisory committees; Sobi: Membership on an entity's Board of Directors or advisory committees.
The role of thrombophilia testing in clinical practice remains controversial. In the absence of clinical trials evaluating thrombophilia testing and its effect on decision-making and clinical outcomes, the utility of thrombophilia testing is largely guided by expert opinion. Thrombophilia testing is frequently requested and performed in patients with a family history of thrombosis, in patients with established thrombosis and in women with pregnancy complications. The merits and pitfalls of thrombophilia testing in these scenarios will be discussed and debated.

Stephan Moll, MD

University of North Carolina School of Medicine, Chapel Hill, NC

Deborah M. Siegal, MD

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada

See more of: Spotlight Sessions